

1 **A microbiota-directed complementary food intervention in 12-18-month-old Bangladeshi children**
2 **improves linear growth**

3

4 Ishita Mostafa MPH^{1,5}, Matthew C. Hibberd PhD^{2,3,4}, Steven J. Hartman BS^{2,3,4}, Md Hasan Hafizur
5 Rahman MPH¹, Mustafa Mahfuz PhD^{1,5}, S. M. Tafsir Hasan MSc¹, Per Ashorn MD⁵, Michael J.
6 Barratt PhD^{2,3,4}, Tahmeed Ahmed PhD¹⁺, Jeffrey I. Gordon MD^{2,3,4+*}

7

8

9 ¹International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka 1212, Bangladesh

10

11 ²Edison Family Center for Genome Sciences and Systems Biology, Washington University School of
12 Medicine, St. Louis, MO 63110 USA

13

14 ³Center for Gut Microbiome and Nutrition Research, Washington University School of Medicine, St.
15 Louis, MO 63110 USA

16

17 ⁴Department of Pathology and Immunology, Washington University School of Medicine, St. Louis,
18 MO 63110 USA

19

20 ⁵Center for Child, Adolescent, and Maternal Health Research, Faculty of Medicine and Health
21 Technology, Tampere University and Tampere University Hospital, Tampere, Finland

22

23 ⁺Co-senior authors

24

25 *Address correspondence to:

26

27 Jeffrey I. Gordon MD

28 The Edison Family Center for Genome Sciences and Systems Biology

29 4515 McKinley Ave

30 St. Louis, MO 63110

31 Phone: 314-362-7243

32 jgordon@wustl.edu

33

34 SUMMARY

35 Background

36 Globally, stunting affects ~150 million children under five, while wasting affects nearly 50 million.
37 Current interventions have had limited effectiveness in ameliorating long-term sequelae of
38 undernutrition including stunting, cognitive deficits and immune dysfunction. Disrupted development
39 of the gut microbiota has been linked to the pathogenesis of undernutrition, providing potentially new
40 treatment approaches.

41 Methods

42 124 Bangladeshi children with moderate acute malnutrition (MAM) enrolled (at 12-18 months) in a
43 previously reported 3-month RCT of a microbiota-directed complementary food (MDCF-2) were
44 followed for two years. Weight and length were monitored by anthropometry, the abundances of
45 bacterial strains were assessed by quantifying metagenome-assembled genomes (MAGs) in serially
46 collected fecal samples and levels of growth-associated proteins were measured in plasma.

47 Findings

48 Children who had received MDCF-2 were significantly less stunted during follow-up than those who
49 received a standard ready-to-use supplementary food (RUSF) [linear mixed-effects model, $\beta_{\text{treatment group}}$
50 $\times \text{study week}$ (95% CI) = 0.002 (0.001, 0.003); $P=0.004$]. They also had elevated fecal abundances of
51 *Agathobacter faecis*, *Blautia massiliensis*, *Lachnospira* and *Dialister*, plus increased levels of a group
52 of 37 plasma proteins (linear model; FDR-adjusted $P<0.1$), including IGF-1, neurotrophin receptor
53 NTRK2 and multiple proteins linked to musculoskeletal and CNS development, that persisted for 6-
54 months post-intervention.

55 Interpretation

56 MDCF-2 treatment of Bangladeshi children with MAM, which produced significant improvements in
57 wasting during intervention, also reduced stunting during follow-up. These results suggest that the
58 effectiveness of supplementary foods for undernutrition may be improved by including ingredients
59 that sponsor healthy microbiota-host co-development.

60 Funding

61 This work was supported by the BMGF (Grants OPP1134649/INV-000247).

62 ClinicalTrials.gov identifier: NCT04015999

63

64 **Introduction**

65 Childhood undernutrition is a public health priority manifested by impaired ponderal and linear
66 growth (wasting and stunting), immune and metabolic dysfunction, altered central nervous system
67 (CNS) development as well as other physiologic abnormalities¹. Undernutrition is typically classified
68 using anthropometric assessments. It is estimated that globally, ~50 million children under the age of
69 five suffer from acute malnutrition (wasting); those with moderate acute malnutrition (MAM) have
70 weight-for-length Z scores (WLZ) that are 2-3 standard deviations below the median (WLZ -2 to -3)
71 of a reference multi-national cohort of children with healthy growth, while WLZ <-3 is characteristic
72 of those with non-oedematous severe acute malnutrition (SAM)². Stunting is the most prevalent form
73 of childhood malnutrition, affecting around 150 million children with nearly one in three afflicted in
74 parts of South Asia and sub-Saharan Africa³. Stunting often begins prenatally and is linked to
75 maternal risk factors (height, age, education); after birth, it may continue to worsen under the
76 influence of environmental stressors (e.g. poor diet, infection) until at least 2-years-of-age, whereafter
77 LAZ scores remain low for children in many low-income countries⁴⁻⁶. Children under-5 who are
78 stunted are five times more likely to die than non-stunted children and those who survive may suffer
79 impairments in immune and cognitive development and have increased risk for chronic illnesses in
80 adult life^{7,8}.

81 Wasting and stunting are typically treated differently. Wasting is treated with high energy
82 micronutrient-fortified ready-to-use supplementary or therapeutic foods (RUSF/RUTF) in the
83 community or in hospital-based settings^{9,10}. Approaches to treating stunting have been multifaceted,
84 including strategies to reduce enteropathogen burden and environmental enteric dysfunction (EED)¹¹
85 through access to clean water, sanitation, and improved hygiene (WASH), as well as various
86 maternal, infant and young child feeding programs. To date evidence for the relative effectiveness of
87 these approaches has been mixed^{12,13}. Moreover, wasting and stunting frequently co-exist in the same
88 infant/child, either concurrently or at different periods in their development, with co-occurrence being
89 more common in severely wasted children and associated with significantly greater risk of mortality
90 compared to either form of undernutrition alone¹⁴⁻¹⁶. Analyses of longitudinal studies of infant growth
91 in the U.S., Honduras, Ghana and Malawi have found that weight gain in a preceding 3-month
92 interval is associated with linear growth in the following interval^{17,18}. A major challenge in
93 interpreting these results is the lack of deeper knowledge of the underlying physiologic changes that
94 occur within a given individual over time, and how these changes are related mechanistically to their
95 growth trajectories.

96 Given the modest effectiveness of existing interventions, efforts are being made to obtain a
97 more comprehensive view of the biological state or states associated with undernutrition, gather new
98 insights into pathogenesis and identify additional therapeutic targets. One outcome of these efforts is
99 recognition of the contributions of the gut microbiota. Birth cohort studies have disclosed that

100 children with undernutrition have impaired postnatal development of their gut microbial communities
101 compared to their age-matched healthy counterparts. This impaired development (microbiota
102 immaturity) is worse in children with SAM compared to those with MAM and is not repaired by
103 standard therapeutic food¹⁹⁻²¹. Phenotypic comparisons of gnotobiotic mice colonized with fecal
104 microbiota from age-matched healthy children or those with wasting and stunting have revealed
105 bacterial strains whose abundances/expressed functions are higher in healthy microbiota and that are
106 able to ameliorate growth faltering when added to mice colonized with the microbiota from
107 undernourished children²².

108 Based on these findings, gnotobiotic mice were used to ‘screen’ complementary foods
109 commonly consumed in Bangladesh to test whether any had the ability to increase the
110 fitness/expressed beneficial functions of growth associated taxa that are underrepresented during the
111 weaning period in the microbiota of undernourished Bangladeshi children compared to their healthy
112 counterparts. This effort ultimately led to the development of a ‘microbiota-directed complementary
113 food’ prototype (‘MDCF-2’), containing ‘microbiota-active’ ingredients - chickpea, soy flour, peanut
114 paste and green banana - along with vegetable oil, sugar and micronutrients²³. A 3-month randomized
115 controlled trial of MDCF-2 in 12-18-month-old Bangladeshi children with MAM revealed that
116 children who received a MDCF-2 had a significantly greater rate of weight gain (WLZ) compared to
117 children who received a standard RUSF, despite the fact that MDCF-2 had a 15% lower caloric
118 density than the RUSF^{24,25}. The superiority of MDCF-2 was linked to changes in the abundances of
119 bacterial strains (metagenome-assembled genomes, MAGs) including strains of *Prevotella copri* that
120 were significantly associated with improved WLZ and which possessed a distinct repertoire of
121 polysaccharide utilization loci (PULs) compared to non-WLZ-associated *P. copri* MAGs²⁶. The
122 superior ponderal growth of children treated with MDCF-2 was accompanied by increases in the
123 levels of plasma proteins that are biomarkers and mediators of musculoskeletal growth and
124 neurodevelopment, plus decreases in the levels of plasma proteins that are biomarkers and mediators
125 of inflammation²⁵. Nonetheless, at the end of the 3-month intervention, children treated with MDCF-2
126 did not show statistically significant differences in their LAZ scores compared to those who received
127 RUSF.

128 In this report, we describe the results of a 2-year follow-up of these children, which included
129 anthropometry and assessment of the fecal microbiota and plasma proteome. Our results reveal that 3-
130 months of MDCF-2 treatment not only provides a rapid and sustained improvement in ponderal
131 growth, but also leads to superior linear growth in the follow-up period compared to RUSF. These
132 findings, together with corresponding changes in the representation of growth associated MAGs and
133 levels of plasma proteins involved in various facets of growth, provide evidence that the benefits of
134 MDCF-2 treatment extend beyond the period of its administration in this population of Bangladeshi
135 children with MAM.

136 **RESEARCH IN CONTEXT**

137 **Evidence before this study**

138 Undernutrition is the leading cause of death of children under 5-years-of-age worldwide. This
139 multifaceted global health challenge is expected to become more severe in part due to intersecting
140 effects of climate change, increasing economic disparities affecting low- and middle-income countries
141 (LMICs), and continued geopolitical upheaval. Undernutrition not only increases the risk of death but
142 is also associated with persistent sequelae including stunting, immune dysfunction, and cognitive
143 deficits. Numerous epidemiologic studies have shown that undernutrition is not due to food insecurity
144 alone. Moreover, current nutritional interventions, while reducing mortality, have had limited success
145 in overcoming these sequelae.

146 **Added value of this study**

147 We performed a 3-month randomized controlled trial in which a microbiota-directed complementary
148 food formulation (MDCF) was compared to a standard RUSF in 12-18-month-old Bangladeshi
149 children with MAM, who were also stunted. We previously reported that supplementation with
150 MDCF improved ponderal growth compared to RUSF, despite the fact that the latter was more
151 calorically dense. Here we report the results of a 2-year follow-up of these children which revealed
152 significantly better LAZ scores in MDCF-2 compared to RUSF-treated children that was manifested
153 only during the follow-up period. Improved LAZ was accompanied by significant differences in the
154 representation of growth-associated bacterial taxa, plus significant elevations in plasma protein
155 mediators/biomarkers of musculoskeletal growth and neurodevelopment that extended beyond the
156 period of intervention.

157 **Implications of all the available evidence**

158 Children with MAM and SAM have perturbed gut microbial community development that is
159 manifested by alterations in the representation of growth-associated bacterial taxa as well as microbial
160 genes comprising various metabolic pathways. The result of these perturbations are microbial
161 communities whose configurations resemble those of chronologically younger children. Standard
162 nutritional interventions in children do not fully repair these perturbed community states. Our findings
163 suggest that microbiota-directed foods, designed to improve the representation and/or expressed
164 metabolic functions of key gut bacteria, not only improve weight gain but also linear growth and
165 plasma biomarkers of a range of developmental processes. These findings set the stage for additional
166 studies to determine (i) the extent to which linear growth benefits of MDCF-2 are manifested in
167 stunted children who are not also wasted; (ii) whether the observed plasma biomarker
168 signatures/responses to MDCF-2 foreshadow clinical improvements in body composition and
169 cognitive performance, and (iii) optimal conditions for initiating treatment (e.g., age, severity of
170 undernutrition, MDCF dose/duration). Deeper knowledge of these relationships may enable an

171 evolution in policies for treating undernourished children beyond current recommendations that are
172 based largely on considerations of the energy density and macro-/micronutrient content of diets and
173 therapeutic foods.

174 METHODS

175 Human study design

176 The study design for the randomized controlled trial comparing the efficacy of a microbiota-directed
177 complementary food (MDCF-2) and a ready to use supplementary food (RUSF) in promoting weight
178 gain in 12-18-month-old Bangladeshi children with MAM is shown in **Fig 1a**. The clinical study
179 (ClinicalTrials.gov identifier:NCT04015999) was conducted in the Mirpur slum of Dhaka,
180 Bangladesh from December, 2018 to October, 2019 as previously described^{24,25} The protocol was
181 approved by the ethics review committee at the International Centre for Diarrhoeal Disease Research,
182 Bangladesh (icddr,b). Children were screened and enrolled through household surveys in the
183 community by Field Research Assistants and written consent was obtained from the parents of the
184 study participants. Eligible children (male and female) with MAM (WLZ -2 to -3) who met the
185 inclusion criteria were enrolled and randomly assigned to receive either a rice, lentil, milk powder,
186 sugar and soybean oil-based RUSF, or MDCF-2, which contains chickpea flour, soy flour, peanut and
187 green banana plus soybean oil and sugar. A total of 124 children were enrolled (n=62/arm)²⁴. At
188 enrollment (baseline), anthropometric assessments were performed, and fecal and plasma samples
189 were collected from each child. MDCF-2 and RUSF, freshly prepared at the icddr,b Food Processing
190 Facility located in Mirpur were provided to participants twice daily for 3 months under supervision by
191 trained study staff (morning and afternoon, 2 x 25g servings/day). The total energy provided by the
192 supplements was 220-250kcal/day or ~20-25% of the daily recommended energy intake (and 70% of
193 the recommended micronutrients) for healthy 12–18-month-old children. Caregivers were instructed
194 not to feed their children during the 2-hour period before each visit; otherwise, their usual
195 breastfeeding and complementary feeding practices were maintained. Fecal specimens were collected
196 prior to intervention, weekly during the 1st month of intervention, and every 4 weeks during the
197 second and third month of intervention. After cessation of the intervention, fecal sampling was
198 performed at the 1, 6 and 12 months of follow-up. (Note that these follow-up time points relate to the
199 end of *study months* 4, 9 and 15 respectively; **Fig. 1a**). Blood samples were collected prior to
200 intervention, at the end of first and third month of intervention, and at 1, 6 and 12 months of follow-
201 up.

202 Anthropometric assessments were performed by trained field research assistants at enrollment
203 (just prior to treatment), every 15 days during the intervention period, 1 month after cessation of
204 treatment and at 9, 15, 21 and 27 months after enrollment into the study. The presence/absence of any
205 illness during the 7 days preceding each anthropometric assessment was recorded. The weight of each
206 child was determined using a digital scale with 2 g precision (Seca, model 728, Germany). Length
207 was measured using an infantometer (Seca, model 416, Germany), and mid-upper arm circumference
208 (MUAC) was determined to the nearest millimeter (using a non-stretch tape). Each measurement was
209 taken twice at a single timepoint by two separate individuals and the average score was recorded. Z

210 scores were calculated using the new child growth standards of the World Health Organization
211 (WHO)². For each of the four main anthropometric assessments, we modeled the treatment group-
212 specific trajectories using the following linear mixed effects model:

$$\text{anthropometric assessment} \sim \beta_1(\text{week after treatment}) + \beta_2(\text{age at baseline}) + \beta_3(\text{sex}) \quad (1) \\ + \beta_4(\text{illness in prior seven days}) + (1|\text{participant})$$

213 We employed the model below to compare effects between the treatment groups:

$$\text{anthropometric assessment} \sim \beta_1(\text{treatment group} \times \text{week after treatment}) \quad (2) \\ + \beta_2(\text{age at baseline}) + \beta_3(\text{sex}) + \beta_4(\text{illness in prior seven days}) + \beta_5(\text{treatment group}) \\ + \beta_6(\text{week after treatment}) + (1|\text{participant})$$

214 **Biospecimen collection**

215 Fecal and plasma specimens were collected as previously described²⁵. In brief, within 20 minutes of
216 defecation, aliquots of the fecal sample were transferred by the field worker into sterile 2 mL
217 cryovials and transferred into cryo-shippers (Taylor Wharton/ Worthington Industries CX300) that
218 had been pre-charged with liquid nitrogen. Cryo-shippers were transported to the study center where
219 their contents were recorded, and the vials transferred to a -80°C freezer. Venous blood was collected
220 in EDTA-plasma tubes; plasma recovered after centrifugation (3000 x g for 10 minutes at room
221 temperature) was aliquoted into cryovials and stored at -80°C. Specimens were shipped to
222 Washington University in St Louis USA on dry ice and stored at -80°C in a dedicated biospecimen
223 repository prior to analysis, with approval from the Washington University Human Research
224 Protection Office. For this study, 225 fecal samples (n=114 at 6 months follow-up and n=111 at 12
225 months) and 219 plasma samples (n=111 at 6 months follow-up and n=108 at 12 months) were
226 collected/analyzed. Additional fecal and plasma samples included in the analyses described here were
227 collected prior to, during and at the end of the intervention, plus at the 1-month follow-up time point,
228 as previously reported^{25,28}.

229 **Quantification of enteropathogens by multiplex qPCR**

230 The same qPCR assay employed in the treatment phase of the study was applied in the post-treatment
231 follow-up phase to measure 23 bacterial, viral and protozoan enteropathogens²⁵⁻²⁷. Enteropathogen
232 abundances were compared between the treatment groups at the end of treatment, and at 6- and 12-
233 months post-treatment using both Kruskal-Wallis tests applied to log₁₀-transformed enteropathogen
234 abundances at each sampling timepoint and linear, mixed-effects models of the following form:

$$\log_{10}(\text{enteropathogen abundance}) \sim \beta_1(\text{age at sampling}) + \beta_2(\text{sex}) + \beta_3(\text{study week}) \\ + \beta_4(\text{treatment group}) + \beta_5(\text{study week: treatment group}) + \\ (1|\text{participant}) \#(3)$$

$$\log_{10}(\text{enteropathogen abundance}) \sim \beta_1(\text{age at sampling}) + \beta_2(\text{sex}) \\ + \beta_3(\text{illness in prior seven days}) + \beta_4(\text{study week}) + \\ \beta_5(\text{treatment group}) + (1|\text{participant})\#(4)$$

235 Significance for the Kruskal-Wallis test, Eq. 3 (β_5 term) and Eq. 4 (β_3 term) was defined by
236 $q < 0.05$ (P -value adjusted to control for multiple hypotheses using the Benjamini-Hochberg
237 correction²⁹).

238 **Isolation and short-read shotgun sequencing of fecal DNA**

239 DNA was isolated from 225 fecal samples representing the 6- and 12- month post-treatment follow-up
240 timepoints as previously described²⁸ and shotgun metagenomic sequencing libraries were prepared
241 with a modified Nextera XT (Illumina) protocol³⁰. Libraries were quantified, balanced, pooled, and
242 sequenced to a depth of $8.96 \times 10^7 \pm 2.09 \times 10^7$ 150 nt paired-end reads/sample (mean \pm SD) at similar
243 scale and on the same Illumina NovaSeq 6000 sequencing platform (S4 flow cell) as the treatment
244 phase fecal metagenomic sequencing effort described previously²⁸. [Negative (water only) process
245 controls were included in both the treatment phase and follow-up sequencing efforts. Library
246 preparation and sequencing of these samples yielded $6.70 \times 10^4 \pm 3.01 \times 10^4$ (mean \pm SD) reads]. Reads
247 were demultiplexed and pre-processed to remove low-quality bases/reads, as well as reads mapping to
248 the hg19 assembly of the human genome²⁸.

249 **Quantitation of Abundances of Metagenome Assembled Genomes (MAGs)**

250 Pre-processed shotgun data from the 6- and 12- month follow-up time points were mapped using
251 Kallisto (v0.43.0)³¹ to a single quantification index from the set of 1,000 high-quality MAGs
252 (completeness $\geq 90\%$, contamination $< 5\%$) generated from data collected during the treatment phase
253 and 1 month follow-up time point of this study²⁸. The 1,000 MAGs were produced using an assembly
254 strategy in which shotgun sequencing reads generated from fecal samples serially collected from a
255 given trial participant were aggregated and assembled into a 'participant-specific' MAG set. MAGs
256 from all participants were then compared and dereplicated to generate a set of study-wide MAGs.
257 MAGs were considered redundant if they shared 99% average nucleotide identity (ANI)²⁸. Taxonomy
258 was subsequently assigned to these MAGs using a consensus approach based on (i) Kraken (v2.0.8)³²
259 and Bracken (v2.5)³³ plus (ii) the Genome Taxonomy Database Toolkit (GTDB-tk)³⁴ and GTDB
260 database (v0.95). We then mapped fecal shotgun sequencing data from the additional follow-up time
261 points to the 1,000 MAGs assembled previously to facilitate the merging of the datasets. After
262 merging, the dataset contained abundance data for each of the 1,000 MAGs across 928 samples (703
263 samples representing the period from pretreatment through 1 month of follow-up²⁸ and 225 from the
264 6- and 12-month follow-up time points) with matching anthropometric assessments. This dataset was
265 then filtered to exclude MAGs below a threshold count of 5 reads per kilobase per million in $\geq 40\%$
266 of samples, yielding a final dataset containing 851 MAGs.

267 **Principal components analysis**

268 We assayed the stability of the microbiota over the first 12 months of post-intervention follow-up
269 using principal components analysis (PCA) applied to the filtered, VST-transformed dataset spanning
270 treatment and follow-up samples described above. PCA was performed using the ‘prcomp’ function in
271 R (v4.3.2); sample projections and information regarding variance explained by each principal
272 component (PC) were extracted as previously described²⁸. PCs explaining variance above
273 ‘background’ were correlated to the age at which each fecal sample was collected (Pearson)
274 (background defined by applying PCA to a permuted dataset²⁸). PC projections were compared over
275 time and between treatment groups using t-tests, with statistical significance defined as *P*-value <
276 0.05.

277 **Identifying MAGs and MAG features associated with MDCF-2 treatment and/or** 278 **anthropometric recovery**

279 We used linear mixed effects modeling (dream, part of the variancePartition package v1.24.1, in R
280 v4.3.2)³⁵ to relate the untransformed abundances of MAGs to ‘treatment group’, ‘weeks after
281 intervention’ and the interaction of these terms, while controlling for repeated sampling from each
282 participant:

$$\begin{aligned} \text{MAG abundance} \sim & \beta_1(\text{sex}) + \beta_2(\text{age at sampling}) + \beta_3(\text{treatment group}) \\ & + \beta_4(\text{weeks after intervention}) + \beta_5(\text{treatment group} \times \text{weeks after intervention}) \\ & + (1|\text{participant})\#(5) \end{aligned}$$

283 This model was applied to the abundance dataset containing 851 MAGs in fecal samples collected at
284 the end of treatment plus 1, 6, and 12 months into the post-intervention follow-up (defined in the
285 model as 12, 16, 36 and 60 weeks from the start of the trial). Relationships between MAG abundances
286 and terms in the model were considered significant if they displayed $q < 0.05$.

287 We employed gene set enrichment analyses (GSEA; fgsea v3.14)³⁶ to identify similar
288 abundance responses in the set of 75 positively or 147 negatively WLZ-associated MAGs identified in
289 our prior analyses of treatment-phase fecal samples²⁸. MAGs were ranked based on a standardized *z*
290 statistic describing their relationship with terms from the linear mixed effects model described in Eq.
291 5 above, after which GSEA was performed. Sets of MAGs displaying $q < 0.05$ were considered
292 significant.

293 We also performed a differential abundance analysis of MAGs between the MDCF-2 and
294 RUSF treatment groups at each time point using a simplified model (dream, v1.24.1) relating MAG
295 abundance only to the treatment group, with significant differences between groups defined as having
296 a $q < 0.05$. Enrichment analyses for the positively or negatively WLZ-associated MAGs were also
297 applied to comparisons of MAG abundances at each time point using the methods and statistical
298 criteria described above.

299 To identify MAGs whose abundances were associated with the rate of change in LAZ in the
300 follow-up phase, we transformed the filtered MAG abundance dataset using the Variance Stabilizing
301 Transformation (VST)³⁷; we then filtered this dataset to the timeframe spanning the end of treatment
302 and 12-months of follow-up and determined relationships with LAZ using the following model:

$$\begin{aligned} 303 \quad LAZ \sim & \beta_1(\text{sex}) + \beta_2(\text{age at sampling}) + \beta_3(\text{VST} - \text{transformed MAG abundance}) \\ 304 \quad & + \beta_4(\text{weeks after intervention}) + \beta_5(\text{VST} - \text{trans. MAG abundance} \times \text{weeks after intervention}) \\ 305 \quad & + (1|\text{participant}) \#(6) \end{aligned}$$

306 Statistical significance was determined for the β_3 term using ANOVA with a cutoff of $q < 0.05$. We
307 additionally used the β_3 coefficients corresponding to each MAG abundance relationship with LAZ as
308 a ranking factor for GSEA, after which sets of MAGs, grouped by (i) species-level taxonomic
309 assignment, (ii) WLZ-association in the treatment phase and (iii) the presence or absence of encoded
310 metabolic pathways were tested for enrichment (significant enrichments were indicated by $q < 0.05$).
311 Metabolic pathway annotations for MAGs were based on alignment to the mcSEED database and *in*
312 *silico* prediction of pathway presence/absence as previously described²⁸.

313 Aptamer-based plasma proteomic analysis

314 The SomaScan proteomic assay plasma/serum kit (SomaLogic, v4.0) was used as previously
315 described²⁵ to quantify 5,284 proteins in the plasma samples that had been collected from study
316 participants at enrollment and 1, 3, 9 and 15 months after enrollment. Plasma samples were separated
317 into two batches for data acquisition, with the first consisting of samples collected at enrollment, 1-
318 and 3-months (treatment phase), and the latter from 9- and 15-months (follow-up). Each 50 μL aliquot
319 of plasma was incubated with NHS-biotin-tagged aptamer probes ('SOMAmers') to form protein-
320 specific SOMAmer complexes. After immobilization on streptavidin beads, complexes were cleaved,
321 denatured, eluted, and hybridized to customized Agilent DNA microarrays. Arrays were scanned
322 (Agilent SureScan; 5 μm resolution) and the Cy3 fluorescence signal processed using SomaLogic's
323 standardization procedures²⁵. Protein abundances were \log_2 -transformed prior to analysis.

324 To assess whether the 75 plasma proteins that were associated with the rate of weight gain (β -
325 WLZ) in the treatment phase²⁵ were also predictive of the rate of change in WLZ or LAZ during the
326 follow-up period, we first calculated the rate of change of these 75 proteins during treatment (0-3
327 months) for each participant in each treatment arm [$n=113$ samples at enrollment, $n=114$ at the end of
328 treatment]. Next, we calculated the rate of change in WLZ and LAZ in each participant during the
329 follow-up period (months 3-27) and used linear models to relate the rate of change of each protein
330 during treatment to the rate of change of LAZ or WLZ during the follow-up period:

$$331 \quad \text{slope}(\text{WLZ follow-up}) \sim \beta_1(\text{slope}(\text{protein levels treatment phase})) + \beta_2(\text{age at enrollment}) + \beta_3(\text{sex}) \quad (7)$$

332 and

$$333 \quad \text{slope}(\text{LAZ follow-up}) \sim \beta_1(\text{slope}(\text{protein levels treatment phase})) + \beta_2(\text{age at enrollment}) + \beta_3(\text{sex}) \quad (8)$$

334 Significance was assigned after correcting for multiple testing for each anthropometric measure
335 ($q < 0.1$).

336 We applied a linear mixed effects model to test whether any of the proteins significantly
337 associated with anthropometric changes (as defined from Eq. 7 and 8) exhibited a greater rate of
338 change in one or other treatment group during the treatment phase:

$$339 \quad \text{protein abundance} \sim \beta_1(\text{study week}) + \beta_2(\text{treatment group}) + \quad (9)$$
$$340 \quad \beta_3(\text{study week:treatment group}) + (1/\text{participant})$$

341 ANOVA was used to test for statistical significance, with correction for multiple testing ($q < 0.1$). To
342 determine if the resulting proteins were significantly associated with a treatment group as a whole, we
343 applied a one-way t-test to the $\beta_3(\text{study week:treatment group})$ coefficients collected for each protein.

344 For plasma samples collected at the 6- and 12-month follow-up time points [$n=111$ samples at
345 month 6 and $n=108$ at month 12], a linear model was applied to identify LAZ-associated plasma
346 proteins whose levels were differentially abundant between the two treatment arms at each time point:

$$347 \quad \text{protein abundance} \sim \beta_1(\text{treatment group}) \quad (10)$$

349 We applied a one-way t-test to the $\beta_1(\text{treatment group})$ coefficients for proteins at the 6- and 12-month
350 follow-up time points and subsequently applied a false-discovery rate correction on the P -values
351 obtained from the t-tests applied to Eq. 9 β_3 and Eq. 10 β_1 coefficients ($q < 0.05$).

352 **Illness and dietary intake during the follow-up period**

353 Each child was monitored for illness daily for one continuous week ending at or near the time of
354 anthropometry data collection at the end of treatment and at the end of 1, 6, 12, 18, and 24 months of
355 post-intervention follow-up. Food frequency questionnaires were administered at the same time points
356 and used to calculate Minimum Acceptable Diet (MAD) per World Health Organization and UNICEF
357 guidelines³⁸. MAD is only valid for children 6-23 months old. Children in our clinical trial surpassed
358 this range between 1- and 6-months of post-intervention follow-up. Therefore, we applied chi-squared
359 tests comparing whether MAD criteria were met for the MDCF-2 versus the RUSF treatment groups
360 at the 1- and 6-month follow-up timepoints. Significance was defined by $P < 0.05$.

361 **Role of the funding source**

362 The funders of this work were not involved in designing the study or in the collection, analysis,
363 interpretation of the data, and did not participate in writing the manuscript.

364

365

366 RESULTS

367 Anthropometric recovery of children with MAM during and after treatment with MDCF-2

368 Out of 124 children, 118 (n=59/arm) completed the intervention; their anthropometric characteristics
369 at the end of the treatment phase (i.e., the beginning of follow-up) are shown in **Table 1**. For each
370 time point of anthropometric assessment (**Figure 1a**), we modeled the treatment group-specific
371 trajectories as well as differences between groups using linear mixed effects models, controlling for,
372 treatment time, age, sex and the presence of any illnesses in the 7 days prior to anthropometry (see
373 *Methods*, Eq. 1 and 2; **Supplementary Table S1A,B**). The superior WLZ achieved by children in the
374 MDCF-2 arm at the end of treatment (**Figure 1b**) was maintained through follow-up, though the
375 difference in rate of change of WLZ between the groups was no longer significant ($P=0.22$; linear
376 mixed effects model) (**Figure 1c**; **Supplementary Table S1B**). Weight-for-age (WAZ) also trended
377 higher in the follow-up period for MDCF-2 treated children, although this difference was not
378 statistically significant (**Supplementary Table S1B**).

379 Linear growth faltering often begins *in utero* and may continue to worsen during the first 2
380 postnatal years in low-income countries such as Bangladesh⁴. In our randomized controlled trial, LAZ
381 was not different between the two groups during the treatment phase ($P=0.6$ linear mixed effects
382 model; **Figure 1d**, **Supplementary Table S1A**). However, in the 24-month post-intervention follow-
383 up period (**Table 2**), we observed a statistically significant decrease in the rate of LAZ decline in
384 children that had received 3 months of MDCF-2 supplementation compared to those that had received
385 RUSF ($P=0.004$; **Figure 1e**; **Supplementary Table S1B**). To examine whether differences in the
386 quality of diets consumed by children in the follow-up period may have contributed to differences in
387 linear growth trajectories between the intervention groups, we examined food frequency data
388 collected during follow-up period and compared the Minimum Acceptable Diet (MAD) scores for
389 each group. MAD is an indicator of infant and young child feeding (IYCF) practices for 6-23-month-
390 old children that is used to describe the quality of a child's diet and is defined as the percentage of
391 children (in the 6–23-month age range) who consumed a minimum acceptable diet during the
392 previous day³⁸. MAD was not significantly different between the MDCF-2 and RUSF groups at the 1-
393 and 6-month follow-up time points when this measurement was applicable based on age (chi-squared
394 $P>0.05$, **Supplementary Table S1C**). Taken together, these results indicate that compared to the
395 more calorically dense RUSF used in this RCT of children with MAM, a relatively short intervention
396 with MDCF-2 provided improvements not only in their ponderal growth, but also a sustained
397 difference in linear growth that is not explained by differences in quality of diet consumed by children
398 during follow-up.

399 Effects of MDCF-2 on the microbiota

400 We next assessed whether the improvements in anthropometry during the follow-up period were
401 associated with durable changes in the microbiota resulting from treatment with MDCF-2. Of the 118
402 children who completed the intervention, we collected fecal samples from 114 after 6 months of
403 follow up (n=57/treatment group), and 111 at 12 months (n=56, MDCF-2 treatment group; n=55,
404 RUSF treatment group) (i.e., there was only 6% loss to follow-up at 12 months).

405 We employed a qPCR assay²⁵ to quantify the abundances of 23 bacterial, viral and protozoan
406 enteropathogens in each child's fecal samples (**Supplementary Table S2A**). Neither pairwise
407 comparisons of enteropathogen abundances, nor the total number of detected enteropathogens at the
408 cessation of treatment, or at 6- or 12-months post-treatment revealed any significant differences
409 between the treatment groups (Kruskal-Wallis tests, $q > 0.05$). Likewise, linear mixed-effects models
410 designed to identify the effects of interactions between treatment group and time after cessation of
411 treatment (controlling for age and sex) on enteropathogen abundances failed to identify significant
412 differences between the treatment groups (**Supplementary Table S2B**). We subsequently examined
413 the relationship between the enteropathogen levels and illnesses reported in the seven days prior to
414 fecal sample collection; these analyses revealed a significant positive relationship between diarrheal
415 illness and (i) the total number of enteropathogens detected and (ii) the abundances of *C. jejuni*,
416 enterotoxigenic *E. coli*, Cryptosporidium and diarrheal illness, independent of age, sex, timepoint or
417 treatment group (**Supplementary Table S2C**).

418 To analyze the fecal microbial communities of MDCF-2- and RUSF-treated participants
419 sampled during the post-intervention follow-up period, we mapped shotgun sequencing data
420 generated from fecal samples collected at the 6- and 12-month follow-up timepoints to the set of
421 1,000 high-quality metagenome assembled genomes (MAGs) assembled from fecal shotgun
422 sequencing data collected during the treatment phase of the study²⁸. These datasets were merged with
423 data generated from the treatment phase of the study and one-month follow-up, after which filtering
424 was applied to exclude sparsely represented MAGs. This effort resulted in a dataset comprising 851
425 MAGs across 928 samples with matched anthropometry data (see *Methods*).

426 We applied a principal components analysis (PCA) to the full MAG dataset spanning
427 pretreatment through 12 months of follow-up. We identified principal components (PCs) that
428 explained variance above background (*Methods*). PC1, explaining 19.2% of variance, was
429 significantly correlated with a child's age at the time of sample collection (Pearson $P < 2.2 \times 10^{-16}$). We
430 therefore used the projection of each sample along PC1 as a dimensionality-reduced metric of
431 microbiota 'age'. As expected, given that the treatment and early follow-up phases of the study
432 occurred in children at an age when the microbiota is developing¹⁹, there was a significant change in
433 position along PC1 between samples collected at 1 and 6 months and 6 and 12 months of follow-up
434 ($P = 1.87 \times 10^{-9}$ and $P = 6.43 \times 10^{-7}$, respectively; t-test). However, we observed no significant difference

435 between the PC1 projections of samples obtained from participants in the MDCF-2 and RUSF arms
436 during the follow-up phase, when children were between 16- and 33-months-old ($P>0.05$, t-tests).

437 We proceeded to analyze the abundances of each individual MAG over time during the period
438 between the end of treatment and 12 months of follow-up in children formerly treated with MDCF-2
439 or RUSF. As in the treatment phase, no single MAG met our criteria for statistically significant
440 differential abundance or differential rate of change of abundance between the two treatment groups
441 during this period ($q>0.05$, linear mixed effects model, Eq. 5; **Supplementary Table S3A**). However,
442 employing gene set enrichment analysis (GSEA), we compared the representation of the MAGs
443 previously identified²⁸ as significantly positively ($n=75$) or negatively ($n=147$) associated with WLZ
444 during the treatment phase, in fecal samples obtained at the end of treatment and at 1, 6 and 12
445 months of follow-up. MAGs that were positively associated with WLZ were enriched in the MDCF-2
446 treatment group, while MAGs that were negatively associated with WLZ were enriched in the RUSF
447 group at the end of treatment, and at one month of follow-up (GSEA $q<0.05$, **Fig. 2a**,
448 **Supplementary Table S3C,D**). The enrichment of positively WLZ-associated MAGs was driven by
449 15 MAGs assigned to the species *Agathobacter rectalis* (5 MAGs), *Blautia massiliensis* (5 MAGs),
450 *CAG-217 sp00436335* (family Acutalibacteraceae, 2 MAGs), *ER4 sp000765235* (family
451 Oscillospiraceae, 2 MAGs), *Parolsenella catena* (2 MAGs), and *Prevotella copri* (2 MAGs; **Fig. 2b**).
452 Notably, these two *P. copri* MAGs were Bg0018 and Bg0019 – both positively associated with WLZ
453 - that express polysaccharide utilization loci involved in the metabolism of glycans enriched in
454 MDCF-2 compared to RUSF²⁸. The enrichment of this set of 15 MAGS was no longer statistically
455 significant at the 6-month post-intervention time point (GSEA $q>0.05$).

456 Given the effect of prior MDCF-2 treatment on LAZ in the follow-up period, we initially used
457 the same approach we had employed to identify WLZ-associated MAGs to search for LAZ-associated
458 MAGs in the follow-up phase. Our efforts to model the relationship between MAG abundance and
459 LAZ yielded only one significantly associated MAG, Bg0899, which was negatively associated and
460 classified within the family Lachnospiraceae ($q<0.05$, linear mixed effects model (Eq.4),
461 **Supplementary Table S3E**). Therefore, we expanded this analysis by ranking MAGs based on the
462 coefficient describing their relationship with LAZ over time in the follow-up period [$\beta_3(\text{MAG}$
463 abundance x weeks after intervention)] and applying GSEA to sets of MAGs defined by their species
464 assignments. Using this approach, we identified a group of four species (*Agathobacter faecis*, *Blautia*
465 *massiliensis*, *Lachnospira sp000436475* and *Dialister sp000434475* and) that were positively
466 associated with LAZ ($q<0.05$, GSEA, **Supplementary Table S3F**). *Agathobacter* produce the
467 beneficial short chain fatty acid (SCFA) butyrate through fermentation of mono- di- and oligo-
468 saccharides³⁹, while *Blautia massiliensis* is reported to be enriched in carbohydrate transport and
469 metabolism capacities compared with other species in the genus *Blautia*, with acetate a key product of

470 fermentation^{40,41}. *Lachnospira* and *Dialister* also contribute to the fermentation of carbohydrates and
471 production of SCFA.

472 Finally, we looked for relationships between MAGs that were significantly associated with
473 WLZ in the treatment and follow-up phases of the trial. This analysis revealed a group of 75 MAGs
474 positively correlated with WLZ in the treatment phase²⁸ that were also enriched among LAZ
475 correlated MAGs during follow-up ($q=1.24 \times 10^{-4}$, GSEA applied to MAGs ranked by their LAZ
476 association; **Supplementary Table S3G**). Notably, the 25 MAGs that had the strongest associations
477 with both LAZ and WLZ were predominantly assigned to the families Lachnospiraceae (n=12
478 MAGs), Ruminococcaceae (n=8) or Oscillospiraceae (n=3) (**Supplementary Table S3H**). An
479 analysis of MAGs whose abundances were positively associated with LAZ yielded no significantly
480 enriched metabolic pathways (GSEA, $q>0.05$). However, DNA abundance is an imprecise proxy for
481 functional activity and additional analyses involving microbial RNA-Seq are required to characterize
482 the relationship between *expressed* community functions influenced by MDCF-2 and linear growth.

483 **Effects of MDCF-2 on the plasma proteome**

484 We next sought to determine whether the plasma proteins positively (n=70) or negatively (n=5)
485 associated with improvements in weight gain (β -WLZ) during the treatment phase [n=113 plasma
486 samples analyzed at enrollment and n=114 at the end of treatment]²⁵ were also associated with the rate
487 of change in either WLZ or LAZ during follow-up. We used linear models, accounting for age and
488 sex (Eq. 7,8) to regress the rate of change of each of the 75 proteins to the rate of change of WLZ or
489 LAZ during the 24-month follow-up phase. This analysis disclosed that while none of the proteins
490 remained significantly associated with ponderal growth (WLZ) (**Supplementary Table S4A**), 37
491 were significantly positively associated with rate of change of LAZ during follow-up ($q<0.1$, **Fig. 3a**
492 **Supplementary Table S4B**); all of these were positively associated with WLZ during the treatment
493 phase²⁵. They include biomarkers/mediators of musculoskeletal development; e.g., cell adhesion
494 molecule-related/down-regulated by oncogenes (CDON) which is a positive regulator of
495 myogenesis⁴², dermatopontin (DPT) which accelerates collagen fibrillogenesis⁴³, thrombospondins-3
496 and -4 (THBS3,4) which are involved in tissue remodeling and skeletal maturation via interaction
497 with the extracellular matrix^{44,45}, plus a number of collagens (e.g., COL15A1, COL9A1, COL6A3).
498 Other notable proteins among the 37 positively associated with LAZ include insulin-like growth
499 factor-1 (IGF-1) which acts in concert with growth hormone to control linear growth in children⁴⁶ and
500 a Wnt inhibitor, secreted frizzled-related protein 4 (SFRP4), involved in formation of bone cortex⁴⁷.
501 The list also includes effectors of CNS development: e.g., RET which encodes the receptor tyrosine
502 kinase for glial cell derived neurotrophic factor (GDNF)⁴⁸; the axon guidance protein SLIT and NTRK
503 like family member 5 (SLITRK5)⁴⁹, BDNF/NT-3 growth factors receptor (NTRK2) which is involved
504 in synaptogenesis and learning and memory⁵⁰, plus roundabout homolog 2 (ROBO2), an axon

505 guidance receptor recently reported to also promote osteoblast differentiation and mineralization⁵¹
506 (see **Fig. 3b** for complete list of these proteins and their functional annotations).

507 For each of the 37 LAZ-associated proteins, we applied a linear mixed-effects model (Eq. 9 in
508 *Methods*) to obtain their differential rates of change in levels during the treatment phase between the
509 MDCF-2 and RUSF groups (**Supplementary Table S4C**). A one-way t-test was then performed on
510 the $\beta_3(\text{month:treatment group})$ coefficients; each coefficient represents the differential rate of change
511 in the level of each protein between the two groups during treatment. The analysis revealed that these
512 proteins, as a group, were significantly enriched in the MDCF-2 arm (FDR corrected $q < 0.05$; **Fig 3c**).
513 We next used a linear model (Eq. 10 in *Methods*) to test whether the LAZ-associated proteins were
514 differentially abundant between the MDCF-2 and RUSF treatment arms at month 6 and month 12 of
515 the follow-up period [n=111 plasma samples analyzed at the end of month 6; n=108 at the end of
516 month 12] (**Supplementary Table S4D,E**). While none of the 37 proteins exhibited significant
517 differences in their levels between treatment arms at either follow-up time point ($q > 0.1$), as a group
518 their levels in plasma was significantly higher in MDCF-2 compared to RUSF treated children at the
519 6-month follow-up time point [(one-way t-test applied to the $\beta_1(\text{treatment group})$ coefficients in Eq.
520 10 with $q < 0.05$ (**Fig. 3c**)]. By 12 months of follow-up, this enrichment was no longer evident. Taken
521 together, these results indicate that the 3-month intervention with MDCF-2 in 12-18-month-old
522 Bangladeshi children with MAM improved ponderal and linear growth and produced increases in the
523 levels of a group of plasma biomarkers/ mediators of growth and CNS development that were evident
524 for at least 6 months after cessation of treatment.

525 **Discussion**

526 In this study, we performed a two-year follow-up of a cohort of 12-18-month-old Bangladeshi
527 children who had been treated for moderate acute malnutrition (MAM) for 3 months with either a
528 microbiota-directed complementary food (MDCF-2), or a standard ready-to-use supplementary food
529 (RUSF)²⁵. We assessed their anthropometric recovery and quantified changes in the representation of
530 >800 bacterial strains (MAGs) present in their fecal microbial communities, plus levels of plasma
531 proteins during the follow-up period. WLZ scores, which were significantly improved by MDCF-2
532 compared to RUSF at the end of treatment, remained higher in the MDCF-2 group during follow-up.
533 Moreover, despite there being no significant differences in LAZ between the groups at the end of the
534 3-month intervention, there was a significant difference between the groups during follow-up;
535 namely, the rate of decline in LAZ, which is commonly seen in children in the first few years of life in
536 resource-poor countries in South Asia and Africa^{4,5}, was significantly less in children who had
537 received MDCF-2 in the antecedent treatment phase. There were no significant differences in diet
538 quality or enteropathogen burden between the treatment groups during the follow-up period. We
539 identified a number of MAGs that were correlated with LAZ after cessation of the intervention,

540 including strains capable of fermenting dietary glycans to short chain fatty acids. Moreover, several
541 MAGs belonging to Lachnospiraceae, Ruminococcaceae and Oscillospiraceae were linked to both
542 WLZ during treatment and LAZ during follow-up.

543 The improved linear growth in MDCF-2-treated children in the follow-up period was
544 associated with elevated levels of a group of 37 plasma proteins that persisted for at least 6 months
545 after cessation of treatment; these proteins were previously identified as being positively correlated
546 with WLZ during the treatment phase of the study²⁵; their functions are linked to various facets of
547 healthy growth, including musculoskeletal development, central nervous system development and cell
548 growth/proliferation. This set of plasma proteins represent candidate ‘leading indicators’ of linear
549 growth recovery in undernourished Bangladeshi children. Moreover, they provide a rationale for
550 including more specific clinical measurements beyond anthropometry to more comprehensively
551 characterize physiologic responses to MDCF-2; for example, musculoskeletal and cognitive
552 development which may be manifest over longer time frames than changes in WLZ (or LAZ).

553 There is a paucity of sufficiently powered longitudinal studies and randomized controlled
554 trials that incorporate detailed characterization of the functional capacity of the microbiome, such as
555 shotgun sequencing of fecal DNA to define changes in the representation of MAGs, and microbial
556 RNA-Seq to relate the expression of metabolic pathways and their products to clinical outcomes. One
557 recent example of the importance of this kind of approach employed a metagenomic analysis of fecal
558 samples from 335 infants/young children living in rural Zimbabwe where there is a high prevalence of
559 stunting. This study revealed that genomic features of the fecal microbial community, in particular,
560 the representation carbohydrate degradation pathways (rather than taxonomic representation), were
561 predictive of linear growth of children during the period of complementary feeding⁵². This finding is
562 consistent with our own studies of growth responses to MDCF-2 in children with MAM; namely that
563 improvements in ponderal growth are driven by specific strains (MAGs) of *P. copri* that express the
564 appropriate repertoire of carbohydrate active enzymes (CAZymes) required to utilize MDCF-2
565 glycans²⁸. Additional studies incorporating similar types of analyses (microbial gene expression, fecal
566 metabolomics) will be required to characterize the *functional* maturation of the microbiota, as well as
567 the relationship between changes in functional activity that link responses to MDCF-2 with linear
568 growth outcomes (including the durability of changes in metabolic activities both during and
569 following intervention).

570 Our study was relatively small (124 children with MAM enrolled) and the duration of
571 intervention was short (3 months). Moreover, it was not designed to investigate stunting as a primary
572 outcome^{24,25}. It will be important to perform larger, longer controlled studies in Bangladesh, as well as
573 in different geographic/sociodemographic settings, to (i) examine the generalizability of the effects of
574 MDCF-2 on stunting without concurrent wasting, versus when both are present in the same child, and
575 (ii) assess the impact of timing (i.e., chronologic age) of initiation of intervention based on the

576 representation of target MAGs in childrens' gut microbial communities - a process that could be
577 guided by affordable point-of-care diagnostic approaches (e.g., qPCR assays of growth-discriminatory
578 MAGs). In addition, it is important to consider and optimize the dose of the MDCF-2 formulation –
579 especially its constituent glycans - and the duration of treatment. Moreover, the background diet
580 consumed by children may have a significant impact on their growth; based on data from food
581 frequency questionnaires, we had previously found that children who consumed more of the
582 complementary food types present in MDCF-2 in their normal diets during the intervention were more
583 likely to be in the upper quartile of improved weight gain (WLZ)²⁵.

584 Taken together, our findings suggest that the effects of MDCF-2 on the gut microbiota of
585 undernourished Bangladeshi children extend beyond weight gain to include improvements in linear
586 growth. Dissecting the mechanistic underpinnings of the effects of the microbial community on
587 growth requires additional research. For example, preclinical studies conducted in gnotobiotic mice
588 colonized with defined communities of cultured, genome-sequenced bacteria corresponding to WLZ-
589 and/or LAZ-associated MAGs represent one approach for dissecting the contributions of MDCF-2
590 responsive organisms to host pathways involved in ponderal and linear growth as well as other aspects
591 of development, including neurodevelopment. A precedent for such an approach has been established.
592 By combining analyses of microbial community assembly, microbial gene expression and metabolism
593 of glycan constituents of MDCF-2 with single nucleus RNA-Seq and mass spectrometric analyses of
594 the intestine we have confirmed the key role played by specific *P. copri* strains in metabolizing
595 MDCF-2 glycans, promoting weight gain, and stimulating the activities of metabolic pathways
596 involved in lipid, amino acid, carbohydrate plus other facets of energy metabolism in intestinal
597 epithelial cells⁵³. A similar strategy should now be employed to examine the role of cultured
598 representatives of the LAZ-associated MAGs identified in the current study on different aspects of
599 linear growth, including accretion of lean body mass, bone development, and maturation of the
600 epiphyseal plates.

601 **References**

- 602 1. Black RE, Allen LH, Bhutta ZA, et al. Maternal and Child Undernutrition Study Group. Maternal
603 and child undernutrition: global and regional exposures and health consequences. *Lancet* 2008;
604 **371**: 243-60.
- 605 2. World Health Organization. WHO child growth standards: growth velocity based on weight,
606 length and head circumference: methods and development (2009).
607 <https://www.who.int/publications/i/item/9789241547635>
- 608 3. United Nations Children's Fund (UNICEF), World Health Organization (WHO), International
609 Bank for Reconstruction and Development/The World Bank. Levels and trends in child

- 610 malnutrition: UNICEF / WHO / World Bank Group Joint Child Malnutrition Estimates: Key
611 findings of the 2023 edition. New York: UNICEF and WHO. 2023.
- 612 4. de Onis, M., and Branca, F. Childhood stunting: a global perspective. *Maternal & Child*
613 *Nutrition* 12: 12–26.
- 614 5. de Onis M, Borghi E, Arimond M, et al. Prevalence thresholds for wasting, overweight and
615 stunting in children under 5 years. *Public Health Nutrition* 2019; **22**:1–5.
- 616 6. Kumar P, Rashmi R, Muhammad T, Srivastava S. Factors contributing to the reduction in
617 childhood stunting in Bangladesh: a pooled data analysis from the Bangladesh demographic and
618 health surveys of 2004 and 2017–18. *BMC Public Health* 2021; **21**: 2101.
- 619 7. Victora CG, Adair L, Fall C, et al. for the Maternal and Child Undernutrition Group. Maternal
620 and child undernutrition: consequences for adult health and human capital. *Lancet* 2008; **371**:
621 340-357.
- 622 8. Dewey KG, Begum K. Long-term consequences of stunting in early life. *Matern Child Nutr.*
623 2011; Suppl **3**: 5-18.
- 624 9. Cichon B, Das JK, Salam RA, et al. Effectiveness of Dietary Management for Moderate Wasting
625 among Children > 6 Months of Age-A Systematic Review and Meta-Analysis Exploring Different
626 Types, Quantities, and Durations. *Nutrients* 2023; **15**: 1076.
- 627 10. WHO. Guideline: Updates on the Management of Severe Acute Malnutrition in Infants and
628 Children. World Health Organization; Geneva, Switzerland: 2013. PMID: 24649519.
- 629 11. Budge S, Parker AH, Hutchings PT, Garbutt C. Environmental enteric dysfunction and child
630 stunting. *Nutr Rev.* 2019; **77**: 240–53.
- 631 12. Dewey KG. Reducing stunting by improving maternal, infant and young child nutrition in regions
632 such as South Asia: evidence, challenges and opportunities. *Matern Child Nutr.* 2016; **12** Suppl 1:
633 27-38.
- 634 13. Goudet SM, Bogin BA, Madise NJ, Griffiths PL. Nutritional interventions for preventing stunting
635 in children (birth to 59 months) living in urban slums in low- and middle-income countries
636 (LMIC). *Cochrane Database Syst Rev.* 2019; **6**: CD011695.
- 637 14. Odei Obeng-Amoako GA, Wamani H, Conkle J, et al. Concurrently wasted and stunted 6-59
638 months children admitted to the outpatient therapeutic feeding programme in Karamoja, Uganda:
639 Prevalence, characteristics, treatment outcomes and response. *PLoS One* 2020; **15**: e0230480.
- 640 15. Isanaka S, Hitchings MDT, Berthé F, Briend A, Grais RF. Linear growth faltering and the role of
641 weight attainment: Prospective analysis of young children recovering from severe wasting in
642 Niger. *Matern Child Nutr.* 2019; **15**: e12817.
- 643 16. Thurstans S, Sessions N, Dolan C, et al. The relationship between wasting and stunting in young
644 children: A systematic review. *Matern Child Nutr.* 2022; **18**: e13246.

- 645 17. Dewey KG, Hawck MG, Brown KH, Lartey A, Cohen RJ, Peerson JM. Infant weight-for-length
646 is positively associated with subsequent linear growth across four different populations. *Matern*
647 *Child Nutr.* 2005; **1**: 11-20.
- 648 18. Maleta K, Virtanen SM, Espo M, Kulmala T, Ashorn P. Seasonality of growth and the
649 relationship between weight and height gain in children under three years of age in rural Malawi.
650 *Acta Paediatr.* 2003; **92**: 491-7.
- 651 19. Subramanian S, Huq S, Yatsunenkov T, et al. Persistent gut microbiota immaturity in malnourished
652 Bangladeshi children. *Nature* 2014; **510**: 417-21.
- 653 20. Barratt MJ, Ahmed T, Gordon JI. Gut microbiome development and childhood undernutrition.
654 *Cell Host & Microbe* 2022; **30**: 617-626.
- 655 21. Raman AS, Gehrig JL, Venkatesh S, et al. A sparse covarying unit that describes healthy and
656 impaired human gut microbiota development. *Science* 2019; **365**: eaau4735.
- 657 22. Blanton LV, Charbonneau MR, Salih T, et al. Gut bacteria that prevent growth impairments
658 transmitted by microbiota from malnourished children. *Science* 2016; **351**: aad3311.
- 659 23. Gehrig JL, Venkatesh S, Chang HW, et al. Effects of microbiota-directed foods in gnotobiotic
660 animals and undernourished children. *Science* 2019; **365**: eaau4732.
- 661 24. Mostafa I, Nahar N, Islam MM, et al. Proof-of-concept study of the efficacy of a microbiota-
662 directed complementary food formulation (MDCF) for treating moderate acute malnutrition. *BMC*
663 *Public Health* 2020; **20**: 242.
- 664 25. Chen RY, Mostafa I, Hibberd MC, et al. A Microbiota-Directed Food Intervention for
665 Undernourished Children. *N Engl J Med.* 2021; **384**: 1517-1528.
- 666 26. Liu J, Platts-Mills JA, Juma J, et al. Use of quantitative molecular diagnostic methods to identify
667 causes of diarrhoea in children: a reanalysis of the GEMS case-control study. *Lancet* 2016; **388**:
668 1291–1301.
- 669 27. Platts-Mills JA, Liu J, Rogawski ET, et al. Use of quantitative molecular diagnostic methods to
670 assess the aetiology, burden, and clinical characteristics of diarrhoea in children in low-resource
671 settings: a reanalysis of the MAL-ED cohort study. *Lancet Glob. Health* 2018; **6**: e1309–e1318.
- 672 28. Hibberd MC, Webber DM, Rodionov DA, et al. Bioactive glycans in a microbiome-directed food
673 for malnourished children. *Nature* 2024; **625**: 157-165.
- 674 29. Benjamini Y and Hochberg Y. Controlling the false discovery rate: a practical and powerful
675 approach to multiple testing. *J R Stat Soc Series B Stat Methodol.* 1995; **57**: 289-300.
- 676 30. Baym M, Kryazhimskiy S, Lieberman TD, Chung H, Desai MM, Kishony R. Inexpensive
677 multiplexed library preparation for megabase-sized genomes. *PLoS One* 2015; **10**: e0128036.
- 678 31. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification.
679 *Nat Biotechnol.* 2016; **34**: 525-7.

- 680 32. Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. *Genome Biol.*
681 2019; **20**: 257.
- 682 33. Lu J, Breitwieser FP, Thielen P, and Salzberg S. Bracken: estimating species abundance in
683 metagenomics data. *PeerJ. Computer Science* 2017; **3**: e104.
- 684 34. Chaumeil PA, Mussig AJ, Hugenholtz P, Parks DH. GTDB-Tk: a toolkit to classify genomes with
685 the Genome Taxonomy Database. *Bioinformatics* 2019; **36**: 1925–7.
- 686 35. Hoffman GE and Roussos P. Dream: powerful differential expression analysis for repeated
687 measures designs. *Bioinformatics* 2020; **37**: 192–201.
- 688 36. Korotkevich G, Sukho V, Budin N, et al., Fast gene set enrichment analysis. *bioRxiv* 2021;
689 <https://doi.org/10.1101/060012>.
- 690 37. Love, M.I., Huber, W. and Anders, S. Moderated estimation of fold change and dispersion for
691 RNA-seq data with DESeq2. *Genome Biol.* 2014; **15**: 550.
- 692 38. Indicators for assessing infant and young child feeding practices: definitions and measurement
693 methods. Geneva: World Health Organization and the United Nations Children’s Fund
694 (UNICEF), 2021.
- 695 39. Duncan, S. H., Barcenilla, A., Stewart, C. S., Pryde, S. E., and Flint, H. J. Acetate utilization and
696 butyryl coenzyme A (CoA):acetate-CoA transferase in butyrate-producing bacteria from the
697 human large intestine. *Appl. Environ. Microbiol.* 2002; **68**: 5186–5190.
- 698 40. Durand GA, Pham T, Ndongo S, et al. *Blautia massiliensis* sp. nov., isolated from a fresh human
699 fecal sample and emended description of the genus *Blautia*. *Anaerobe* 2017; **43**: 47-55.
- 700 41. Hou X, Wu N, Ren S, et al. Profiling *Blautia* at high taxonomic resolution reveals correlations
701 with cognitive dysfunction in Chinese children with Down syndrome. *Front Cell Infect Microbiol.*
702 2023; **13**: 1109889.
- 703 42. Cole F, Zhang W, Geyra A, Kang JS, Krauss R.S. Positive regulation of myogenic bHLH factors
704 and skeletal muscle development by the cell surface receptor CDO. *Dev Cell* 2004; **7**: 843–854.
- 705 43. Takeda U, Utani A, Wu J, et al. Targeted disruption of dermatopontin causes abnormal collagen
706 fibrillogenesis. *J Invest Dermatol.* 2002; **119**: 678-83.
- 707 44. Hankenson KD, Hormuzdi SG, Meganck JA, Bornstein P. Mice with a disruption of the
708 thrombospondin 3 gene differ in geometric and biomechanical properties of bone and have
709 accelerated development of the femoral head. *Mol Cell Biol.* 2005; **25**: 5599-606.
- 710 45. Stenina-Adognravi O, Plow EF. Thrombospondin-4 in tissue remodeling. *Matrix Biol.* 2019; **75**-
711 **76**: 300-313.

- 712 46. David A, Hwa V, Metherell LA, et al. Evidence for a continuum of genetic, phenotypic, and
713 biochemical abnormalities in children with growth hormone insensitivity. *Endocr Rev.* 2011; **32**:
714 472-97.
- 715 47. Kiper POS, Saito H, Gori F, et al. Cortical-Bone Fragility--Insights from sFRP4 Deficiency in
716 Pyle's Disease. *N Engl J Med.* 2016; **374**: 2553-2562.
- 717 48. Baloh RH, Enomoto H, Johnson EM Jr, Milbrandt J. The GDNF family ligands and receptors -
718 implications for neural development. *Curr Opin Neurobiol.* 2000; **10**: 103-10.
- 719 49. Liu Y, Zhang L, Mei R, et al. The Role of SliTrk5 in Central Nervous System. *Biomed Res Int.*
720 2022; 4678026.
- 721 50. Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. *Nature*
722 *Reviews Neuroscience.* 2013; **14**: 7–23.
- 723 51. Yuan N, Wang X, He M. Robo2 promotes osteoblast differentiation and mineralization through
724 autophagy and is activated by parathyroid hormone induction. *Ann Anat.* 2023; **248**: 152070.
- 725 52. Robertson RC, Edens TJ, Carr L, et al. The gut microbiome and early-life growth in a population
726 with high prevalence of stunting. *Nat Commun.* 2023; **14**: 654.
- 727 53. Chang HW, Lee EM, Wang Y, et al. *Prevotella copri* and microbiota members mediate the
728 beneficial effects of a therapeutic food for malnutrition. *Nat Microbiol.* 2024; **9**: 922-937

729 **Contributors**

730 I.M., with assistance from H.H.R., M.M., T.H. conducted the long-term follow-up for the clinical trial
731 and collected anthropometry and clinical metadata. I.M., M.C.H. and M.J.B. analyzed dietary data and
732 anthropometry as reported in Figure 1 and Tables 1 and 2. M.C.H. analyzed the enteropathogen qPCR
733 data, mapped shotgun sequencing data to MAGs and conducted analyses of MAG abundance
734 associations with prior MDCF-2 treatment and/or anthropometry that are reported in Figure 2. S.J.H.
735 analyzed the correlations between plasma protein levels and LAZ or WLZ scores reported in Figure 3.
736 M.J.B. oversaw databases of clinical metadata and the biospecimen archive. T.A. and J.I.G.
737 supervised this research project. I.M., M.J.B. M.C.H. and J.I.G. wrote the paper with invaluable input
738 from co-authors.

739 **Data sharing**


740 The data supporting the findings of this study are available within the supplementary materials;
741 shotgun sequencing data in raw format (prior to post-processing and data analysis) have been
742 deposited at the European Nucleotide Archive (ENA) under study accession PRJEB66487.

743 **Declaration of interests**

744 The authors declare no competing interests.

745 **Acknowledgments:**


746 We are grateful to the families of study participants and icddr,b investigators and staff for their
747 contributions to the collection of biospecimens and data reported here. We appreciate the support of
748 the Bill and Melinda Gates Foundation and the Governments of Bangladesh and Canada for providing
749 core/unrestricted support to icddr,b. We thank Su Deng, Kazi Ahsan, Martin Meier, Jessica
750 Hoisington-Lopez, and MariaLynn Crosby for their technical assistance with processing
751 biospecimens. The support of members of the Genome Technology Access Core (GTAC) at
752 Washington University School of Medicine in shotgun sequencing of fecal DNA and enteropathogen
753 qPCR is greatly appreciated.



754


755 **Figure 1. Anthropometric trajectories during treatment with MDCF-2 or RUSF and during the**
 756 **two year post-intervention follow-up period. (a)** Trial design, including timing of biospecimen
 757 collection for analysis of the microbiome and plasma proteome. **(b,c)** Weight-for-length Z-score
 758 (WLZ) trajectories during the three months of MDCF-2 or RUSF treatment (panel b) and during the
 759 two years of post-intervention follow-up (panel c). **(d,e)** Length-for-age Z-score (LAZ) trajectories
 760 during the three months of MDCF-2 versus RUSF treatment phase of the trial (panel d) or the two
 761 years of post-intervention follow-up (panel e). Each plot indicates a simple linear fit of the data for the
 762 MDCF-2 (blue) and RUSF (red) treatment groups along with the 95% confidence interval. The linear,
 763 mixed effects model for each anthropometric assessment (Eq. 2; *Methods*) was used to determine the
 764 coefficient (β) and statistical significance (P) for the specified effect. For the treatment phase analysis,
 765 the beginning of nutritional intervention was used as the baseline measurement, whereas for the
 766 follow-up analysis, the baseline used was the end of 3-month nutritional intervention.

767



768

769 **Figure 2. Differences in bacterial MAG abundances between fecal samples collected from**
 770 **MDCF-2- and RUSF-treated trial participants during the post-intervention follow-up. (a)** The
 771 enrichment of groups of positively (red) or negatively (blue) WZ-associated MAGs after ranking by
 772 differential abundance between the MDCF-2 or RUSF groups at end of treatment and at the 1-, 6-, or
 773 12- month post-intervention time points. Normalized Enrichment Scores (NES) were determined by
 774 GSEA. Points representing significant NES significant ($q < 0.05$) are outlined in black. **(b)** Taxonomic
 775 assignments of MAGs driving the enrichment of positively WZ-associated MAGs in the analysis
 776 depicted in (a). Species assignments are shown for taxa containing >1 MAG.



777

778 **Fig 3 - Effects of MDCF-2 on the plasma proteome of children with MAM during nutritional**
 779 **intervention and in the follow-up period. (a)** Volcano plot of WLZ-associated plasma proteins that
 780 are also associated with LAZ responses during the post-treatment follow-up period. The linear model
 781 described under the plot was applied to relate the rate of change for each participant in the levels of
 782 proteins during the treatment-phase to the rate of change of LAZ during the follow-up. Significant
 783 LAZ-predictive proteins ($q < 0.1$) are colored in orange. **(b)** Annotated functions of the 37 plasma
 784 proteins associated with the effect of MDCF-2 on LAZ during the follow-up period. **(c)** Association
 785 of the 37 proteins with treatment arm during the 3-month treatment phase and at the 6-month follow-
 786 up time point. One-way t-tests were applied to the β_3 coefficient in Eq. 9 and the β_1 coefficient in Eq.
 787 10 (see *Methods*, $q < 0.05$) at each time point to test the statistical significance of their enrichment in
 788 either the MDCF-2 or RUSF treatment arm.

| Characteristic | MDCF-2 | RUSF | β_1 (treatment group) [†] | P-value [‡] |
|---|------------------|------------------|--|----------------------|
| | mean \pm SD | | | |
| Number of participants | 59 | 59 | | |
| Age at completion of intervention (mo.) | 18.6 \pm 1.92 | 18.9 \pm 1.94 | -0.155 | 0.662 |
| Sex - Female (percent) [‡] | 34 (58) | 33 (56) | | 1 |
| WLZ | -1.88 \pm 0.56 | -2.13 \pm 0.62 | 0.255 | 0.022 |
| WAZ | -2.39 \pm 0.70 | -2.56 \pm 0.72 | 0.15 | 0.252 |
| LAZ | -2.08 \pm 1.08 | -2.06 \pm 1.02 | -0.065 | 0.737 |
| MUAC (cm) | 13.2 \pm 0.48 | 13.1 \pm 0.46 | 0.117 | 0.162 |
| Weight (kg) | 7.99 \pm 0.77 | 8.10 \pm 0.72 | 0.143 | 0.241 |
| Length (cm) | 76.3 \pm 3.2 | 76.0 \pm 3.4 | -0.133 | 0.813 |

789 **Table 1: Anthropometric characteristics of children in each study arm at the end of the 3-month**
790 **intervention (beginning of follow-up phase).** [†] Model: anthropometry $\sim \beta_1$ (treatment group) +
791 β_2 (age at baseline) + β_3 (sex) + β_4 (illness in prior 7 days). Note that the 'age at baseline' term was
792 omitted when 'age at baseline' was tested. [‡] Fisher's Exact Test.

793

| Months of follow-up after intervention | MDCF-2 (n=59) | RUSF (n=59) | Difference (95% CI) |
|--|---------------------|------------------|---------------------|
| | LAZ (mean \pm SD) | | |
| 1 | -2.09 \pm 1.07 | -2.09 \pm 1.00 | - |
| 6 | -2.28 \pm 1.00 | -2.31 \pm 0.92 | 0.03 (-0.32, 0.39) |
| 12 | -2.24 \pm 0.93 | -2.42 \pm 0.86 | 0.18 (-0.16, 0.52) |
| 18 | -2.26 \pm 0.96 | -2.42 \pm 0.87 | 0.16 (-0.18, 0.51) |
| 24 | -2.09 \pm 0.92 | -2.22 \pm 0.80 | 0.13 (-0.20, 0.46) |

794 **Table 2: LAZ scores of participants in each study arm during the 24-month follow-up period.**

795

796 **List of Supplementary Materials**

797 **Supplementary Table S1.** Analyses of anthropometry data

798 **Supplementary Table S2:** Analysis of enteropathogen abundances

799 **Supplementary Table S3:** Analysis of metagenome-assembled genome (MAG) abundances

800 **Supplementary Table S4.** Plasma protein levels related to anthropometric responses and treatment

801